3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Neuroendocrine Tumors
7
Neoplasms
6
Colorectal Neoplasms
5
Carcinoma, Hepatocellular
5
Carcinoid Tumor
5
Stomach Neoplasms
4
Esophageal Neoplasms
4
Acromegaly
4
Weight Loss
3
Rectal Neoplasms
3
Pancreatic Neoplasms
3
Diarrhea
3
Carcinoma
3
Breast Neoplasms
3
Vipoma
2
Thymoma
2
Somatostatinoma
2
Pituitary Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Malnutrition
2
Intestinal Obstruction
2
Insulinoma
2
Glucagonoma
2
Colonic Neoplasms
2
Carcinoma, Islet Cell
2
Adenoma, Islet Cell
2
Zollinger-Ellison Syndrome
1
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Interventions
Octreotide
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Malignant Carcinoid Syndrome
×
Octreotide
×
Clear all
NCT00412061
2014-11-21
RADIANT-2
Novartis
Phase 3
Completed
429 enrolled
13 charts